# EDGAR Filing Document

**Accession Number:** 0001421642
**File Stem:** 0001171843-26-003717
**Filing Date:** 2026-5
**Character Count:** 5129
**Document Hash:** 7a5e5ef9acffad95f2b4cf7039c3a670
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-003717.hdr.sgml**: 20260527

**ACCESSION NUMBER**: 0001171843-26-003717

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260527

**FILED AS OF DATE**: 20260527

**DATE AS OF CHANGE**: 20260527

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Satellos Bioscience Inc.
- **CENTRAL INDEX KEY:** 0001421642
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43107
- **FILM NUMBER:** 261022132

**BUSINESS ADDRESS:**
- **STREET 1:** ROYAL BANK PLAZA, S. TOWER, 200 BAY ST.
- **STREET 2:** SUITE 2800
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5J 2J1
- **BUSINESS PHONE:** 416-708-0522

**MAIL ADDRESS:**
- **STREET 1:** ROYAL BANK PLAZA, S. TOWER, 200 BAY ST.
- **STREET 2:** SUITE 2800
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5J 2J1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ICO THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20071218

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of May 2026**

Commission File Number: **001-43107**

**SATELLOS BIOSCIENCE INC.**

(Translation of registrant's name into English)

**Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800 Toronto, Ontario, ON M5J 2J3**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ X ]

------

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

---

| | |
|:---|:---|
| <u>**Exhibit**</u> | <u>**Description**</u> |
| [99.1](exh_991.htm) | [Satellos to Participate in Upcoming Investor Conferences](exh_991.htm) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;SATELLOS BIOSCIENCE INC.&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: May 27, 2026 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Elizabeth Williams, CPA, CA&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Elizabeth Williams, CPA, CA |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Satellos to Participate in Upcoming Investor Conferences**

TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- **Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL)** ("**Satellos**" or the "**Company**"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that members of the Company management team will participate in the following investor conferences in June.

**Jefferies Global Healthcare Conference**

Date: Thursday, June 4, 2026

Presentation: 11:05 a.m.

Location: New York, NY

**Oppenheimer CNS & Neuro-Muscular Summit**

Date: Wednesday, June 10

Panel: *Next-Generation Therapeutics in Genetic Muscle Disorders*, 10:15 a.m.

Location: Miami, FL

The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company website, and a replay will be available following the presentation.

Members of the Satellos leadership team will also be available for one-on-one investor meetings during the conferences.

**ABOUT SATELLOS BIOSCIENCE INC.**

Satellos is a clinical-stage drug development company advancing SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to reset the body's natural muscle repair and regeneration process in degenerative muscle diseases. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a protein that is a key regulator of the body's natural muscle repair and regeneration biology, which Satellos discovered is disrupted in DMD and other degenerative conditions. By inhibiting AAK1, SAT-3247 is designed to re-establish a critical biochemical signal needed to guide this process, in a dystrophin-independent manner. This mechanistic feature offers SAT-3247 the potential for broad applicability as either a stand-alone treatment to potentially enhance muscle and function, or as adjunctive therapy alongside other approaches. Satellos has identified additional degenerative muscle diseases where enhancing muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.

**CONTACTS**

Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com

Media: Emily Williams, Senior Director of Communications, media@satellos.com